Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Scholar Rock Holding Corporation (SRRK)
USD53.92
+0.14 (+0.25%)
US NASDAQ Healthcare Biotechnology
Address
301 Binney Street 2142
Cambridge, MA, US
Cambridge, MA, US
CEO
David L. Hallal
Website
scholarrock.com
IPO
2018-05-25
CIK 1727196 ISIN US80706P1030
Description
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD53.92
+0.14 (+0.25%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.68
Float Shares
92.41M
Free Float %
80.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.74% | +6.01% | -0.67% | +6.98% | +63.58% | +11.67% | +56.66% | +490.52% | +72.90% | +217.35% | +217.35% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Buy
Price Targets & DCF
Current price
53.92
Low
50.00
-7.3%
Consensus
57.86
+7.3%
Median
58.00
+7.6%
High
65.00
+20.6%
DCF (Unlevered)
1.79
-96.7%
DCF (Levered)
1.87
-96.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 14 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
62.00
+15.0%
|
| Last Quarter | 4 |
57.00
+5.7%
|
| Last Year | 12 |
53.42
-0.9%
|
| All Time | 18 |
47.11
-12.6%
|
Quality scores
Altman Z-Score
8.23
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-33.2% Q1'26: -23.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -23,411.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+14.9% Q1'26: +13.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.29× Q1'26: -0.50× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 12 EPS Ana. |
Dec 2027 12 Rev. Ana. 12 EPS Ana. |
Dec 2028 12 Rev. Ana. 11 EPS Ana. |
Dec 2029 11 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
20.49M
est: 18.08M (+13.3%)
|
15.40M
est: 18.50M (-16.7%)
|
18.82M
est: 19.17M (-1.8%)
|
33.19M
est: 33.15M (+0.1%)
|
—
|
—
est: 153.8K (-100.0%)
|
9.44M
1.32M – 15.23M
+6,035.4% YoY
|
155.52M
117.91M – 193.54M
+1,547.6% YoY
|
353.03M
346.36M – 359.69M
+127.0% YoY
|
560.93M
323.19M – 1.07B
+58.9% YoY
|
831.25M
478.94M – 1.58B
+48.2% YoY
|
| EBITDA |
-53.24M
est: -3.62M (-1,372.1%)
|
-85.39M
est: -3.70M (-2,208.0%)
|
-127.29M
est: -3.83M (-3,220.8%)
|
-129.48M
est: -6.63M (-1,853.2%)
|
-237.52M
|
-369.39M
est: 30.8K (-1,200,620.0%)
|
1.89M
263.5K – 3.05M
+6,035.5% YoY
|
31.10M
23.58M – 38.71M
+1,547.6% YoY
|
70.61M
69.27M – 71.94M
+127.0% YoY
|
112.19M
64.64M – 213.20M
+58.9% YoY
|
166.25M
95.79M – 315.94M
+48.2% YoY
|
| EBIT |
-54.54M
est: -3.62M (-1,408.2%)
|
-86.88M
est: -3.70M (-2,248.3%)
|
-129.92M
est: -3.83M (-3,289.3%)
|
-132.47M
est: -6.63M (-1,898.2%)
|
-239.46M
|
-371.05M
est: 30.8K (-1,206,008.5%)
|
1.89M
263.5K – 3.05M
+6,035.5% YoY
|
31.10M
23.58M – 38.71M
+1,547.6% YoY
|
70.61M
69.27M – 71.94M
+127.0% YoY
|
112.19M
64.64M – 213.20M
+58.9% YoY
|
166.25M
95.79M – 315.94M
+48.2% YoY
|
| Net Income |
-51.00M
est: -188.29M (+72.9%)
|
-86.48M
est: -256.75M (+66.3%)
|
-131.80M
est: -344.36M (+61.7%)
|
-134.50M
est: -159.86M (+15.9%)
|
-246.29M
est: -239.01M (-3.0%)
|
-377.94M
est: -390.11M (+3.1%)
|
-375.20M
-431.38M – -206.92M
+3.8% YoY
|
-298.38M
-360.67M – -204.52M
+20.5% YoY
|
-171.99M
-257.01M – -28.43M
+42.4% YoY
|
-24.85M
-53.94M – -11.16M
+85.5% YoY
|
161.09M
72.33M – 349.65M
+748.2% YoY
|
| SGA |
20.82M
est: 26.24M (-20.7%)
|
28.22M
est: 26.85M (+5.1%)
|
40.27M
est: 27.81M (+44.8%)
|
42.62M
est: 48.10M (-11.4%)
|
67.50M
|
176.21M
est: 197.7K (+89,043.2%)
|
12.13M
1.69M – 19.56M
+6,035.4% YoY
|
199.81M
151.50M – 248.67M
+1,547.6% YoY
|
453.58M
445.02M – 462.14M
+127.0% YoY
|
720.70M
415.24M – 1.37B
+58.9% YoY
|
1.07B
615.35M – 2.03B
+48.2% YoY
|
| EPS |
-1.80
est: -1.89 (+4.6%)
|
-2.77
est: -2.57 (-7.7%)
|
-3.59
est: -3.45 (-4.1%)
|
-2.21
est: -2.17 (-2.1%)
|
-2.47
est: -2.43 (-1.7%)
|
-3.29
est: -3.44 (+4.3%)
|
-3.17
-3.76 – -1.80
+7.8% YoY
|
-2.49
-3.14 – -1.78
+21.4% YoY
|
-1.37
-2.24 – -0.25
+45.0% YoY
|
-0.22
-0.47 – -0.10
+84.2% YoY
|
1.40
0.63 – 3.05
+748.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-303.46M
OE per share TTM
-2.59
Owner's Yield
-5.13%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
178.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
54
Total invested
123.66M
Insider transactions (90d)
1
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Artal Group S.A. | 10.33M | 19.40% | 10.33M | — | 10.33M | — | OO | Bermuda | 2022-06-24 | ↗ |
| 2 | Artal International Management S.A. | 10.33M | 19.40% | 10.33M | — | 10.33M | — | OO | Bermuda | 2022-06-24 | ↗ |
| 3 | Artal International S.C.A. | 10.33M | 19.40% | 10.33M | — | 10.33M | — | OO | Bermuda | 2022-06-24 | ↗ |
| 4 | Invus Public Equities Advisors, LLC | 10.33M | 19.40% | 10.33M | — | 10.33M | — | OO | Bermuda | 2022-06-24 | ↗ |
| 5 | Invus Public Equities, L.P. | 10.33M | 19.40% | 10.33M | — | 10.33M | — | PN | Bermuda | 2022-06-24 | ↗ |
| 6 | Mr. Amaury Wittouck | 10.33M | 19.40% | 10.33M | — | 10.33M | — | IN | Bermuda | 2022-06-24 | ↗ |
| 7 | Stichting Administratiekantoor Westend | 10.33M | 19.40% | 10.33M | — | 10.33M | — | OO | Bermuda | 2022-06-24 | ↗ |
| 8 | Westend S.A. | 10.33M | 19.40% | 10.33M | — | 10.33M | — | OO | Bermuda | 2022-06-24 | ↗ |
| 9 | Srinivas Akkaraju, MD, PhD | 5.68M | 10.80% | 12.4K | 5.66M | 12.4K | 11.00 | IN | — | 2023-02-14 | ↗ |
| 10 | Samsara BioCapital GP, LLC | 5.66M | 10.70% | — | 5.66M | — | 11.00 | OO | — | 2023-02-14 | ↗ |
| 11 | Samsara BioCapital, L.P. | 5.66M | 10.70% | — | 5.66M | — | 11.00 | PN | — | 2023-02-14 | ↗ |
| 12 | Jeremy C. Green | 5.35M | 9.90% | — | 5.35M | — | 5.35M | HC, IN | Delaware | 2022-06-27 | ↗ |
| 13 | Redmile Group, LLC | 5.35M | 9.90% | — | 5.35M | — | 5.35M | IA, OO | Delaware | 2022-06-27 | ↗ |
| 14 | 52-0556948 | 5.26M | 14.90% | 1.07M | — | 5.26M | — | IA | Maryland | 2022-02-14 | ↗ |
| 15 | (1) BlackRock, Inc. | 4.96M | 6.90% | 4.86M | — | 4.96M | — | HC | Delaware | 2024-01-26 | ↗ |
| 16 | FMR LLC | 3.67M | 15.00% | 617.9K | — | 3.67M | — | HC | Delaware | 2018-06-11 | ↗ |
| 17 | OrbiMed Capital LLC | 2.96M | 4.10% | 2.96M | — | 2.96M | — | IA | Delaware | 2024-02-14 | ↗ |
| 18 | of 5 | 2.96M | 10.00% | 2.96M | — | 2.96M | — | IN, OO | — | 2020-02-14 | ↗ |
| 19 | Amir Nashat | 2.60M | 7.40% | 50.9K | 2.55M | 50.9K | 2.55M | IN | — | 2022-02-11 | ↗ |
| 20 | Brian Chee | 2.55M | 7.30% | — | 2.55M | — | 2.55M | IN | — | 2022-02-11 | ↗ |
| 21 | Bryce Youngren | 2.55M | 7.30% | — | 2.55M | — | 2.55M | IN | — | 2022-02-11 | ↗ |
| 22 | David Barrett | 2.55M | 7.30% | — | 2.55M | — | 2.55M | IN | — | 2022-02-11 | ↗ |
| 23 | Jonathan A. Flint | 2.55M | 7.30% | — | 2.55M | — | 2.55M | IN | — | 2022-02-11 | ↗ |
| 24 | Polaris Venture Management Co VI, L.L.C. | 2.55M | 7.30% | 2.55M | — | 2.55M | — | OO | — | 2022-02-11 | ↗ |
| 25 | Terrance G. McGuire | 2.55M | 7.30% | — | 2.55M | — | 2.55M | IN | — | 2022-02-11 | ↗ |
| 26 | Polaris Venture Partners VI, L.P. | 2.41M | 6.90% | 2.41M | — | 2.41M | — | PN | — | 2022-02-11 | ↗ |
| 27 | 10. | 2.26M | 6.70% | — | 2.26M | — | 2.26M | HC, CO | — | 2021-02-12 | ↗ |
| 28 | 2. | 2.26M | 6.70% | — | 2.26M | — | 2.26M | CO | — | 2021-02-12 | ↗ |
| 29 | Redmile Capital Offshore Master Fund, Ltd. | 1.89M | 5.60% | — | 1.89M | — | — | CO | Delaware | 2021-02-16 | ↗ |
| 30 | OrbiMed Advisors LLC | 1.29M | 1.80% | — | 1.29M | — | — | IA | Delaware | 2024-02-14 | ↗ |
| 31 | Polaris Venture Partners Founders’ Fund VI, L.P. | 140.8K | 0.40% | 140.8K | — | 140.8K | — | PN | — | 2022-02-11 | ↗ |
| 32 | EcoR1 Capital, LLC | — | 11.00% | — | — | — | — | IA, OO | Delaware | 2020-02-14 | ↗ |
| 33 | Oleg Nodelman | — | 11.00% | — | — | — | — | HC, IN | United States | 2020-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
54
-235 vs prev Q
New positions
3
Closed positions
226
Increased
19
Reduced
22
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 15.38M +1.4M (+9.8%) | 677.52M +155.7M (+29.8%) | 13.52% +1.091 pp | 0.03% +0.007 pp | USD24.92 +76.8% | 31 qtrs — |
| 2 | SIREN, L.L.C. | 10.83M +1.6M (+17.0%) | 476.84M +132.4M (+38.4%) | 9.52% +1.311 pp | 14.22% +0.748 pp | USD13.25 +232.5% | 6 qtrs — |
| 3 | BLACKROCK, INC. | 7.22M +456.8K (+6.8%) | 317.91M +66.2M (+26.3%) | 6.35% +0.348 pp | 0.01% +0.001 pp | USD15.51 +184.0% | 6 qtrs — |
| 4 | SAMSARA BIOCAPITAL, LLC | 6.90M +1.3M (+22.9%) | 303.84M +94.8M (+45.4%) | 6.06% +1.085 pp | 31.35% +4.058 pp | USD16.47 +167.5% | 16 qtrs — |
| 5 | PRICE T ROWE ASSOCIATES INC /MD/ | 6.40M -480.6K (-7.0%) | 282.03M +25.7M (+10.0%) | 5.63% -0.478 pp | 0.03% +0.003 pp | USD21.98 +100.4% | 31 qtrs — |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 5.76M +1.2M (+26.7%) | 253.70M +84.4M (+49.9%) | 5.06% +1.031 pp | 0.04% +0.015 pp | USD39.35 +11.9% | 9 qtrs — |
| 7 | REDMILE GROUP, LLC | 5.22M +1.3M (+33.7%) | 229.98M +84.6M (+58.2%) | 4.59% +1.126 pp | 16.94% +2.790 pp | USD20.68 +113.0% | 31 qtrs — |
| 8 | VANGUARD GROUP INC | 5.20M +280.5K (+5.7%) | 228.86M +45.8M (+25.0%) | 4.57% +0.207 pp | 0.00% +0.001 pp | USD21.35 +106.3% | 31 qtrs — |
| 9 | BELLEVUE GROUP AG | 4.06M +812.1K (+25.0%) | 178.69M +57.9M (+47.9%) | 3.57% +0.688 pp | 3.39% +0.876 pp | USD27.44 +60.5% | 27 qtrs — |
| 10 | STATE STREET CORP | 4.03M +271.3K (+7.2%) | 177.72M +37.6M (+26.8%) | 3.55% +0.208 pp | 0.01% +0.001 pp | USD24.28 +81.4% | 30 qtrs — |
| 11 | ORBIS ALLAN GRAY LTD | 3.43M +3.1M (+1,034.5%) | 151.04M +139.8M (+1,241.9%) | 3.02% +2.747 pp | 0.63% +0.585 pp | USD43.45 +1.4% | 2 qtrs — |
| 12 | PARADIGM BIOCAPITAL ADVISORS LP | 3.06M +1.1M (+52.4%) | 134.89M +60.0M (+80.2%) | 2.69% +0.909 pp | 3.44% +1.314 pp | USD38.63 +14.0% | 5 qtrs — |
| 13 | JENNISON ASSOCIATES LLC | 2.80M +1.2M (+74.0%) | 123.13M +63.3M (+105.8%) | 2.46% +1.032 pp | 0.07% +0.039 pp | USD39.90 +10.4% | 3 qtrs — |
| 14 | EVENTIDE ASSET MANAGEMENT, LLC | 2.43M -368.1K (-13.1%) | 107.09M +2.8M (+2.7%) | 2.14% -0.346 pp | 1.67% -0.041 pp | USD17.57 +150.7% | 9 qtrs — |
| 15 | NORGES BANK | 2.08M +2.1M (+100.0%) | 91.60M +91.6M (+100.0%) | 1.83% +1.829 pp | 0.01% +0.010 pp | USD44.05 +0.0% | 1 qtrs NEW |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 2.03M +79.2K (+4.1%) | 89.62M +16.8M (+23.1%) | 1.79% +0.054 pp | 0.01% +0.001 pp | USD19.69 +123.7% | 30 qtrs — |
| 17 | HOOD RIVER CAPITAL MANAGEMENT LLC | 2.03M +12.4K (+0.6%) | 89.28M +14.3M (+19.0%) | 1.78% -0.005 pp | 0.98% +0.093 pp | USD12.93 +240.7% | 9 qtrs — |
| 18 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.95M -71.1K (-3.5%) | 86.02M +10.7M (+14.1%) | 1.72% -0.079 pp | 0.58% +0.045 pp | USD38.16 +15.4% | 5 qtrs — |
| 19 | JANUS HENDERSON GROUP PLC | 1.77M -1.2M (-41.1%) | 78.22M -33.9M (-30.3%) | 1.56% -1.114 pp | 0.04% -0.016 pp | USD36.90 +19.4% | 12 qtrs — |
| 20 | HOLOCENE ADVISORS, LP | 1.39M -1.1M (-43.6%) | 61.10M -30.6M (-33.3%) | 1.22% -0.965 pp | 0.13% -0.081 pp | USD37.24 +18.3% | 2 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 1.32M -238.9K (-15.3%) | 58.33M +122.1K (+0.2%) | 1.16% -0.223 pp | 0.01% +0.000 pp | USD20.38 +116.1% | 25 qtrs — |
| 22 | POLAR CAPITAL HOLDINGS PLC | 1.32M +527.9K (+66.5%) | 58.23M +28.7M (+96.9%) | 1.16% +0.458 pp | 0.23% +0.083 pp | USD25.29 +74.2% | 10 qtrs — |
| 23 | WOODLINE PARTNERS LP | 1.21M +340.0K (+39.0%) | 53.35M +20.9M (+64.5%) | 1.06% +0.292 pp | 0.21% +0.054 pp | USD30.08 +46.4% | 11 qtrs — |
| 24 | PICTET ASSET MANAGEMENT HOLDING SA | 1.20M -127.0K (-9.6%) | 52.68M +3.4M (+6.9%) | 1.05% -0.122 pp | 0.05% +0.004 pp | USD36.41 +21.0% | 5 qtrs — |
| 25 | CAPITAL WORLD INVESTORS | 1.13M +— (+0.0%) | 49.72M +7.7M (+18.3%) | 0.99% -0.009 pp | 0.01% +0.001 pp | USD39.23 +12.3% | 5 qtrs — |
| 26 | BANK OF AMERICA CORP /DE/ | 1.05M +316.9K (+43.2%) | 46.27M +19.0M (+69.4%) | 0.92% +0.273 pp | 0.00% +0.002 pp | USD33.53 +31.4% | 30 qtrs — |
| 27 | UBS GROUP AG | 905.4K -226.4K (-20.0%) | 39.88M -2.3M (-5.4%) | 0.80% -0.208 pp | 0.01% 0.000 pp | USD35.03 +25.7% | 15 qtrs — |
| 28 | STEMPOINT CAPITAL LP | 886.9K +160.7K (+22.1%) | 39.07M +12.0M (+44.5%) | 0.78% +0.136 pp | 6.70% +1.280 pp | USD37.38 +17.8% | 5 qtrs — |
| 29 | ENSIGN PEAK ADVISORS, INC | 835.9K +183.6K (+28.2%) | 36.82M +12.5M (+51.6%) | 0.73% +0.156 pp | 0.07% +0.025 pp | USD37.12 +18.7% | 21 qtrs — |
| 30 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 829.4K +828.8K (+143,150.8%) | 36.54M +36.5M (+165,972.7%) | 0.73% +0.729 pp | 0.04% +0.042 pp | USD44.04 +0.0% | 3 qtrs — |
| 31 | FEDERATED HERMES, INC. | 797.9K -2.5K (-0.3%) | 35.15M +5.3M (+17.9%) | 0.70% -0.009 pp | 0.06% +0.006 pp | USD36.68 +20.1% | 4 qtrs — |
| 32 | NATIONALE-NEDERLANDEN POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. | 769.4K +— (+0.0%) | 33.89M +5.2M (+18.3%) | 0.68% -0.006 pp | 3.01% +0.794 pp | USD38.60 +14.1% | 5 qtrs — |
| 33 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 733.5K -60.7K (-7.6%) | 32.31M +2.7M (+9.3%) | 0.64% -0.060 pp | 1.66% -0.071 pp | USD42.28 +4.2% | 5 qtrs — |
| 34 | NORTHERN TRUST CORP | 721.1K -17.6K (-2.4%) | 31.76M +4.3M (+15.5%) | 0.63% -0.021 pp | 0.00% +0.001 pp | USD16.67 +164.2% | 30 qtrs — |
| 35 | AMERICAN CENTURY COMPANIES INC | 708.3K +22.3K (+3.2%) | 31.20M +5.7M (+22.1%) | 0.62% +0.014 pp | 0.02% +0.003 pp | USD42.82 +2.9% | 5 qtrs — |
| 36 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 702.1K +25.1K (+3.7%) | 30.93M +5.7M (+22.7%) | 0.62% +0.017 pp | 0.00% +0.001 pp | USD22.44 +96.3% | 30 qtrs — |
| 37 | VESTAL POINT CAPITAL, LP | 700.0K -800.0K (-53.3%) | 30.84M -25.0M (-44.8%) | 0.62% -0.715 pp | 1.05% -1.474 pp | USD32.59 +35.2% | 4 qtrs — |
| 38 | LOOMIS SAYLES & CO L P | 691.9K -32.3K (-4.5%) | 30.48M +3.5M (+13.0%) | 0.61% -0.034 pp | 0.04% +0.005 pp | USD43.22 +1.9% | 5 qtrs — |
| 39 | NUVEEN, LLC | 604.4K +110.3K (+22.3%) | 26.62M +8.2M (+44.7%) | 0.53% +0.093 pp | 0.01% +0.002 pp | USD34.85 +26.4% | 4 qtrs — |
| 40 | BNP PARIBAS ARBITRAGE, SNC | 554.6K +534.3K (+2,628.8%) | 24.43M +23.7M (+3,127.8%) | 0.49% +0.470 pp | 0.01% +0.011 pp | USD43.12 +2.2% | 28 qtrs — |
| 41 | FISHER ASSET MANAGEMENT, LLC | 531.4K -1.7K (-0.3%) | 23.41M +3.6M (+17.9%) | 0.47% -0.006 pp | 0.01% +0.001 pp | USD14.58 +202.1% | 11 qtrs — |
| 42 | VOYA INVESTMENT MANAGEMENT LLC | 514.2K +71.1K (+16.0%) | 22.65M +6.1M (+37.3%) | 0.45% +0.059 pp | 0.02% +0.006 pp | USD36.82 +19.6% | 11 qtrs — |
| 43 | CITADEL ADVISORS LLC | 495.9K +361.3K (+268.4%) | 21.85M +16.8M (+335.8%) | 0.44% +0.317 pp | 0.00% +0.003 pp | USD39.66 +11.1% | 27 qtrs — |
| 44 | FIRST TURN MANAGEMENT, LLC | 459.7K +459.7K (+100.0%) | 20.25M +20.3M (+100.0%) | 0.40% +0.404 pp | 2.31% +2.314 pp | USD44.05 +0.0% | 1 qtrs NEW |
| 45 | TWO SIGMA INVESTMENTS, LP | 405.5K +246.5K (+154.9%) | 17.86M +11.9M (+201.6%) | 0.36% +0.215 pp | 0.03% +0.016 pp | USD31.28 +40.8% | 12 qtrs — |
| 46 | MORGAN STANLEY | 372.7K -231.3K (-38.3%) | 16.42M -6.1M (-27.0%) | 0.33% -0.208 pp | 0.00% 0.000 pp | USD30.61 +43.9% | 31 qtrs — |
| 47 | MARSHALL WACE, LLP | 368.0K -605.9K (-62.2%) | 16.21M -20.1M (-55.3%) | 0.32% -0.541 pp | 0.01% -0.022 pp | USD40.72 +8.2% | 8 qtrs — |
| 48 | EAGLE HEALTH INVESTMENTS LP | 363.3K +— (+0.0%) | 16.00M +2.5M (+18.3%) | 0.32% -0.003 pp | 3.52% -0.035 pp | USD35.89 +22.7% | 3 qtrs — |
| 49 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 300.0K +200.0K (+200.0%) | 13.22M +9.5M (+254.9%) | 0.26% +0.175 pp | 0.66% +0.404 pp | USD37.04 +18.9% | 9 qtrs — |
| 50 | CLEARBRIDGE INVESTMENTS, LLC | 295.5K -53.0K (-15.2%) | 13.02M +39.4K (+0.3%) | 0.26% -0.049 pp | 0.01% +0.001 pp | USD13.46 +227.3% | 7 qtrs — |
| 51 | TD ASSET MANAGEMENT INC | 281.4K -31.0K (-9.9%) | 12.40M +763.9K (+6.6%) | 0.25% -0.030 pp | 0.01% +0.001 pp | USD24.41 +80.5% | 31 qtrs — |
| 52 | AQR CAPITAL MANAGEMENT LLC | 280.3K +259.1K (+1,223.8%) | 12.35M +11.6M (+1,465.9%) | 0.25% +0.228 pp | 0.01% +0.006 pp | USD42.90 +2.7% | 10 qtrs — |
| 53 | NAN FUNG TRINITY (HK) LTD | 263.2K +225.6K (+599.3%) | 11.60M +10.2M (+727.2%) | 0.23% +0.198 pp | 0.92% +0.779 pp | USD43.08 +2.3% | 2 qtrs — |
| 54 | CASDIN CAPITAL, LLC | 260.0K +260.0K (+100.0%) | 11.45M +11.5M (+100.0%) | 0.23% +0.229 pp | 0.71% +0.711 pp | USD44.05 +0.0% | 1 qtrs NEW |
| 55 | BARCLAYS PLC | 251.9K +86.5K (+52.3%) | 11.10M +9.8M (+737.3%) | 0.22% +0.075 pp | 0.00% +0.002 pp | USD29.94 +47.1% | 30 qtrs — |
| 56 | RAYMOND JAMES FINANCIAL INC | 245.4K +17.2K (+7.6%) | 10.81M +2.3M (+27.2%) | 0.22% +0.013 pp | 0.00% +0.001 pp | USD38.71 +13.8% | 5 qtrs — |
| 57 | BANK OF NEW YORK MELLON CORP | 232.0K -9.6K (-4.0%) | 10.22M +1.2M (+13.6%) | 0.20% -0.010 pp | 0.00% +0.000 pp | USD18.90 +133.1% | 30 qtrs — |
| 58 | CAPTION MANAGEMENT, LLC | 230.0K -198.2K (-46.3%) | 10.13M -5.8M (-36.5%) | 0.20% -0.178 pp | 0.07% -0.055 pp | USD36.03 +22.3% | 6 qtrs — |
| 59 | DEUTSCHE BANK AG\ | 226.2K +29.0K (+14.7%) | 9.96M +2.6M (+35.7%) | 0.20% +0.024 pp | 0.00% +0.001 pp | USD37.20 +18.4% | 11 qtrs — |
| 60 | ARMISTICE CAPITAL, LLC | 200.0K +200.0K (+100.0%) | 8.81M +8.8M (+100.0%) | 0.18% +0.176 pp | 0.10% +0.105 pp | USD44.05 +0.0% | 1 qtrs NEW |
| 61 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 186.9K -10.4K (-5.3%) | 8.17M +822.1K (+11.2%) | 0.16% -0.011 pp | 0.01% +0.001 pp | USD10.88 +304.9% | 27 qtrs — |
| 62 | MAN GROUP PLC | 182.0K +147.8K (+432.5%) | 8.02M +6.7M (+529.9%) | 0.16% +0.130 pp | 0.01% +0.011 pp | USD41.82 +5.3% | 4 qtrs — |
| 63 | JPMORGAN CHASE & CO | 170.8K -543.2K (-76.1%) | 7.52M -19.1M (-71.7%) | 0.15% -0.483 pp | 0.00% -0.001 pp | USD35.43 +24.3% | 30 qtrs — |
| 64 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 168.5K +8.8K (+5.5%) | 7.42M +1.5M (+24.8%) | 0.15% +0.007 pp | 0.01% +0.002 pp | USD36.46 +20.8% | 4 qtrs — |
| 65 | SPHERA FUNDS MANAGEMENT LTD. | 158.3K +158.3K (+100.0%) | 6.97M +7.0M (+100.0%) | 0.14% +0.139 pp | 1.35% +1.348 pp | USD44.05 +0.0% | 6 qtrs — |
| 66 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 153.8K +23.9K (+18.4%) | 6.77M +1.9M (+40.0%) | 0.14% +0.020 pp | 0.29% +0.092 pp | USD37.43 +17.7% | 3 qtrs — |
| 67 | PEREGRINE CAPITAL MANAGEMENT LLC | 152.9K -2.0K (-1.3%) | 6.73M +964.7K (+16.7%) | 0.13% -0.003 pp | 0.21% +0.033 pp | USD37.24 +18.3% | 2 qtrs — |
| 68 | CANDRIAM S.C.A. | 145.6K -84.3K (-36.7%) | 6.42M -2.1M (-25.1%) | 0.13% -0.076 pp | 0.03% -0.013 pp | USD8.09 +444.5% | 7 qtrs — |
| 69 | RAFFERTY ASSET MANAGEMENT, LLC | 129.1K -12.3K (-8.7%) | 5.69M +422.2K (+8.0%) | 0.11% -0.012 pp | 0.02% +0.003 pp | USD26.37 +67.0% | 9 qtrs — |
| 70 | IA GLOBAL ASSET MANAGEMENT INC. | 123.3K +123.3K (+100.0%) | 5.43M +5.4M (+100.0%) | 0.11% +0.108 pp | 0.07% +0.069 pp | USD44.05 +0.0% | 1 qtrs NEW |
| 71 | SWISS NATIONAL BANK | 123.2K +3.6K (+3.0%) | 5.43M +973.1K (+21.8%) | 0.11% +0.002 pp | 0.00% +0.001 pp | USD23.61 +86.6% | 27 qtrs — |
| 72 | SEI INVESTMENTS CO | 120.5K +3.2K (+2.7%) | 5.31M +940.7K (+21.5%) | 0.11% +0.002 pp | 0.01% +0.001 pp | USD20.22 +117.9% | 9 qtrs — |
| 73 | RHUMBLINE ADVISERS | 108.9K -14.9K (-12.0%) | 4.80M +186.5K (+4.0%) | 0.10% -0.014 pp | 0.00% +0.000 pp | USD16.40 +168.6% | 11 qtrs — |
| 74 | UBS ASSET MANAGEMENT AMERICAS INC | 107.2K -2.7K (-2.5%) | 4.72M +628.6K (+15.4%) | 0.09% -0.003 pp | 0.00% +0.000 pp | USD25.58 +72.2% | 22 qtrs — |
| 75 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 106.2K +106.2K (+100.0%) | 4.68M +4.7M (+100.0%) | 0.09% +0.093 pp | 0.04% +0.037 pp | USD44.05 +0.0% | 1 qtrs NEW |
| 76 | — | 103.2K +103.2K (+100.0%) | 4.55M +4.5M (+100.0%) | 0.09% +0.091 pp | 0.16% +0.163 pp | USD44.05 +0.0% | 1 qtrs NEW |
| 77 | HUDSON BAY CAPITAL MANAGEMENT LP | 100.0K +90.0K (+900.0%) | 4.41M +4.0M (+1,082.9%) | 0.09% +0.079 pp | 0.01% +0.013 pp | USD43.37 +1.6% | 2 qtrs — |
| 78 | ARTIA GLOBAL PARTNERS LP | 96.3K +— (+0.0%) | 4.24M +655.7K (+18.3%) | 0.08% -0.001 pp | 0.68% +0.109 pp | USD32.15 +37.0% | 4 qtrs — |
| 79 | WELLS FARGO & COMPANY/MN | 90.6K +39.3K (+76.6%) | 3.99M +2.1M (+108.8%) | 0.08% +0.034 pp | 0.00% +0.000 pp | USD34.15 +29.0% | 30 qtrs — |
| 80 | JANE STREET GROUP, LLC | 88.5K +88.5K (+100.0%) | 3.90M +3.9M (+100.0%) | 0.08% +0.078 pp | 0.00% +0.001 pp | USD44.05 +0.0% | 1 qtrs NEW |
| 81 | MOODY ALDRICH PARTNERS LLC | 85.3K -16.4K (-16.2%) | 3.76M -31.7K (-0.8%) | 0.08% -0.015 pp | 0.70% -0.018 pp | USD38.15 +15.5% | 5 qtrs — |
| 82 | SG AMERICAS SECURITIES, LLC | 84.3K +72.3K (+602.4%) | 3.72M +3.3M (+731.3%) | 0.07% +0.064 pp | 0.00% +0.003 pp | USD43.08 +2.3% | 6 qtrs — |
| 83 | INVESCO LTD. | 82.5K +14.3K (+21.0%) | 3.63M +1.1M (+43.1%) | 0.07% +0.012 pp | 0.00% +0.000 pp | USD41.05 +7.3% | 12 qtrs — |
| 84 | ALLIANCEBERNSTEIN L.P. | 82.1K -32.0 (0.0%) | 3.62M +558.0K (+18.2%) | 0.07% -0.001 pp | 0.00% +0.000 pp | USD23.39 +88.3% | 10 qtrs — |
| 85 | PICTON MAHONEY ASSET MANAGEMENT | 78.0K +78.0K (+100.0%) | 3.44M +3.4M (+100.0%) | 0.07% +0.069 pp | 0.03% +0.027 pp | USD44.05 +0.0% | 1 qtrs NEW |
| 86 | AISLING CAPITAL MANAGEMENT LP | 77.0K +— (+0.0%) | 3.39M +524.6K (+18.3%) | 0.07% -0.001 pp | 0.71% +0.080 pp | USD37.24 +18.3% | 2 qtrs — |
| 87 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 76.5K -153.8K (-66.8%) | 3.37M -5.2M (-60.7%) | 0.07% -0.137 pp | 0.00% -0.001 pp | USD29.83 +47.7% | 8 qtrs — |
| 88 | ADAR1 CAPITAL MANAGEMENT, LLC | 69.6K +49.5K (+246.4%) | 3.07M +2.3M (+309.8%) | 0.06% +0.043 pp | 0.23% +0.155 pp | USD40.24 +9.5% | 7 qtrs — |
| 89 | DARK FOREST CAPITAL MANAGEMENT LP | 64.5K +64.5K (+100.0%) | 2.84M +2.8M (+100.0%) | 0.06% +0.057 pp | 0.13% +0.130 pp | USD44.05 +0.0% | 1 qtrs NEW |
| 90 | LEGAL & GENERAL GROUP PLC | 63.3K -1.4K (-2.1%) | 2.79M +379.6K (+15.7%) | 0.06% -0.002 pp | 0.00% +0.000 pp | USD23.77 +85.3% | 30 qtrs — |
| 91 | KENNEDY CAPITAL MANAGEMENT LLC | 62.7K +844.0 (+1.4%) | 2.76M +458.3K (+19.9%) | 0.06% +0.000 pp | 0.06% +0.008 pp | USD35.34 +24.6% | 8 qtrs — |
| 92 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 60.8K -1.6K (-2.5%) | 2.68M +356.1K (+15.3%) | 0.05% -0.002 pp | 0.00% +0.000 pp | USD24.62 +78.9% | 30 qtrs — |
| 93 | J. GOLDMAN & CO LP | 60.1K +60.1K (+100.0%) | 2.65M +2.6M (+100.0%) | 0.05% +0.053 pp | 0.07% +0.070 pp | USD44.05 +0.0% | 1 qtrs NEW |
| 94 | STONECREST WEALTH MANAGEMENT, INC. | 59.0K +11.7K (+24.7%) | 2.49M +731.3K (+41.5%) | 0.05% +0.010 pp | 1.01% +0.234 pp | USD38.59 +14.1% | 2 qtrs — |
| 95 | NOMURA HOLDINGS INC | 55.4K +55.4K (+100.0%) | 2.44M +2.4M (+100.0%) | 0.05% +0.049 pp | 0.00% +0.003 pp | USD44.05 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 104 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X - Guru Index ETF GURU | 1.25% | 788.2K | 0.75% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 1.19% | 426.4K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 1.19% | 128.41M | 0.35% |
| 4 | Tema Cardiovascular and Metabolic ETF HRTS | 0.99% | 539.9K | 0.99% |
| 5 | Virtus Biotech Clinical Trials ETF BBC | 0.79% | 454.8K | 0.65% |
| 6 | First Trust Multi-Manager Small Cap Opportunities ETF MMSC | 0.66% | 350.2K | 0.95% |
| 7 | American Century Small Cap Growth Insights ETF ACSG | 0.47% | 119.8K | 0.49% |
| 8 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.47% | 350.4K | 0.19% |
| 9 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.47% | 2.16M | 0.40% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.47% | 342.2K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.59
Neutral
Buys
4
Sells
8
Shares acquired
89.8K
Shares disposed
153.3K
Cash buys
—
Cash sales
4.00
Net activity
-63,491
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | Burow Kristina | Director | M-Exempt | A | Common Stock | 18,000 | 8.36 | 150.5K | 110,871 | D | ↗ |
| 2026-04-16 | Woods Keith | Officer | S-Sale | D | Common Stock | 10,220 | 49.57 | 506.7K | 620,055 | D | ↗ |
| 2026-04-16 | Vaishnaw Akshay | Director / Officer | S-Sale | D | Common Stock | 12,246 | 49.57 | 607.1K | 630,542 | D | ↗ |
| 2026-04-16 | Sinha Vikas | Officer | S-Sale | D | Common Stock | 10,410 | 49.57 | 516.1K | 619,856 | D | ↗ |
| 2026-04-16 | Hallal David | Director / Officer | S-Sale | D | Common Stock | 30,615 | 49.57 | 1.52M | 1,639,034 | D | ↗ |
| 2026-02-23 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 7,427 | 46.94 | 348.6K | 99,502 | D | ↗ |
| 2026-02-17 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 7,989 | 46.53 | 371.7K | 106,929 | D | ↗ |
| 2026-02-17 | Parlavecchio Caryn | Officer | S-Sale | D | Common Stock | 9,035 | 46.53 | 420.4K | 169,087 | D | ↗ |
| 2026-02-17 | Marantz Jing L. | Officer | S-Sale | D | Common Stock | 4,157 | 46.53 | 193.4K | 126,012 | D | ↗ |
| 2026-02-17 | Ho Junlin | Officer | S-Sale | D | Common Stock | 9,580 | 46.53 | 445.7K | 241,545 | D | ↗ |
| 2026-02-09 | Woods Keith | Officer | A-Award | A | Common Stock | 47,021 | 0.00 | — | 630,275 | D | ↗ |
| 2026-02-09 | Vaishnaw Akshay | Director / Officer | A-Award | A | Common Stock | 47,021 | 0.00 | — | 642,788 | D | ↗ |
| 2026-02-09 | Sinha Vikas | Officer | A-Award | A | Common Stock | 47,021 | 0.00 | — | 630,266 | D | ↗ |
| 2026-02-09 | Qatanani Mo | Officer | A-Award | A | Common Stock | 29,258 | 0.00 | — | 114,918 | D | ↗ |
| 2026-02-09 | Parlavecchio Caryn | Officer | A-Award | A | Common Stock | 29,258 | 0.00 | — | 178,122 | D | ↗ |
| 2026-02-09 | Marantz Jing L. | Officer | A-Award | A | Common Stock | 34,482 | 0.00 | — | 130,169 | D | ↗ |
| 2026-02-09 | Ho Junlin | Officer | A-Award | A | Common Stock | 36,572 | 0.00 | — | 251,125 | D | ↗ |
| 2026-02-09 | Hallal David | Director / Officer | A-Award | A | Common Stock | 128,004 | 0.00 | — | 1,669,649 | D | ↗ |
| 2026-01-22 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 2,119 | 45.87 | 97.2K | 98,439 | D | ↗ |
| 2026-01-16 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 8,406 | 44.48 | 373.9K | 100,558 | D | ↗ |
| 2026-01-16 | Parlavecchio Caryn | Officer | S-Sale | D | Common Stock | 6,600 | 44.48 | 293.6K | 148,864 | D | ↗ |
| 2026-01-16 | Marantz Jing L. | Officer | S-Sale | D | Common Stock | 5,798 | 44.48 | 257.9K | 95,687 | D | ↗ |
| 2026-01-16 | Ho Junlin | Officer | S-Sale | D | Common Stock | 8,016 | 44.48 | 356.5K | 214,553 | D | ↗ |
| 2026-01-14 | Qatanani Mo | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,893 | 15.75 | 92.8K | 47,143 | D | ↗ |
| 2026-01-13 | Woods Keith | Officer | S-Sale | D | Common Stock | 16,746 | 42.70 | 715.1K | 583,254 | D | ↗ |
| 2026-01-13 | Vaishnaw Akshay | Director / Officer | S-Sale | D | Common Stock | 20,438 | 42.70 | 872.7K | 595,767 | D | ↗ |
| 2026-01-13 | Sinha Vikas | Officer | S-Sale | D | Common Stock | 16,755 | 42.70 | 715.4K | 583,245 | D | ↗ |
| 2026-01-13 | Hallal David | Director / Officer | S-Sale | D | Common Stock | 57,450 | 42.70 | 2.45M | 1,541,645 | D | ↗ |
| 2025-12-16 | Peng Katie | Director | S-Sale | D | Common Stock | 280 | 44.63 | 12.5K | 32,908 | D | ↗ |
| 2025-12-12 | AKKARAJU SRINIVAS | Director | X-InTheMoney | D | Warrants to Purchase Common Stock | 1,064,804 | 7.35 | 7.83M | 0 | I | ↗ |
| 2025-12-11 | Invus Global Management, LLC | 10% Owner | X-InTheMoney | A | Common Stock | 1,575,008 | 7.35 | 11.58M | 10,825,013 | D | ↗ |
| 2025-12-04 | Qatanani Mo | Officer | M-Exempt | A | Common Stock | 21,093 | 18.08 | 381.4K | 195,682 | D | ↗ |
| 2025-10-08 | Hallal David | Director / Officer | G-Gift | D | Common Stock | 205,000 | 0.00 | — | 1,599,095 | D | ↗ |
| 2025-10-07 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 12,796 | 39.31 | 503.0K | 513,235 | I | ↗ |
| 2025-10-06 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 80,863 | 38.68 | 3.13M | 486,691 | I | ↗ |
| 2025-10-03 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 319,700 | 37.42 | 11.96M | 387,414 | I | ↗ |
| 2025-09-22 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 3,353 | 30.67 | 102.8K | 108,964 | D | ↗ |
| 2025-09-16 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 3,178 | 33.52 | 106.5K | 112,317 | D | ↗ |
| 2025-09-16 | Peng Katie | Director | S-Sale | D | Common Stock | 930 | 32.48 | 30.2K | 33,990 | D | ↗ |
| 2025-08-18 | Parlavecchio Caryn | Officer | S-Sale | D | Common Stock | 2,178 | 31.17 | 67.9K | 155,464 | D | ↗ |
| 2025-07-16 | FLIER JEFFREY S. | Director | S-Sale | D | Common Stock | 11,136 | 40.02 | 445.7K | 0 | I | ↗ |
| 2025-07-08 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 24,066 | 34.44 | 828.9K | 115,495 | D | ↗ |
| 2025-06-23 | FLIER JEFFREY S. | Director | S-Sale | D | Common Stock | 2,766 | 32.74 | 90.5K | 24,070 | D | ↗ |
| 2025-06-16 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 3,668 | 32.00 | 117.4K | 139,561 | D | ↗ |
| 2025-06-16 | Peng Katie | Director | S-Sale | D | Common Stock | 2,977 | 31.96 | 95.1K | 34,974 | D | ↗ |
| 2025-06-16 | Parlavecchio Caryn | Officer | S-Sale | D | Common Stock | 6,186 | 32.00 | 198.0K | 157,642 | D | ↗ |
| 2025-06-16 | Ho Junlin | Officer | S-Sale | D | Common Stock | 7,442 | 32.00 | 238.2K | 222,569 | D | ↗ |
| 2025-06-09 | Ho Junlin | Officer | A-Award | A | Common Stock | 8,571 | 0.00 | — | 230,011 | D | ↗ |
| 2025-05-29 | Vaishnaw Akshay | Director / Officer | S-Sale | D | Common Stock | 1,620 | 30.01 | 48.6K | 616,205 | D | ↗ |
| 2025-05-29 | Reed Joshua | Director | S-Sale | D | Common Stock | 500 | 30.04 | 15.0K | 15,732 | D | ↗ |
| 2025-05-29 | Gilman Michael | Director | S-Sale | D | Common Stock | 630 | 29.22 | 18.4K | 57,961 | D | ↗ |
| 2025-05-29 | FLIER JEFFREY S. | Director | S-Sale | D | Common Stock | 4,975 | 29.84 | 148.4K | 24,070 | D | ↗ |
| 2025-05-29 | Burow Kristina | Director | S-Sale | D | Common Stock | 4,400 | 29.83 | 131.3K | 21,071 | D | ↗ |
| 2025-05-29 | Brudnick Richard | Director | S-Sale | D | Common Stock | 4,675 | 29.63 | 138.5K | 16,457 | D | ↗ |
| 2025-05-22 | Reed Joshua | Director | A-Award | A | Stock Option (Right to Buy) | 9,206 | 30.46 | 280.4K | 9,206 | D | ↗ |
| 2025-05-22 | Peng Katie | Director | A-Award | A | Stock Option (Right to Buy) | 9,206 | 30.46 | 280.4K | 9,206 | D | ↗ |
| 2025-05-22 | Gilman Michael | Director | A-Award | A | Stock Option (Right to Buy) | 9,206 | 30.46 | 280.4K | 9,206 | D | ↗ |
| 2025-05-22 | FLIER JEFFREY S. | Director | A-Award | A | Stock Option (Right to Buy) | 9,206 | 30.46 | 280.4K | 9,206 | D | ↗ |
| 2025-05-22 | Burow Kristina | Director | A-Award | A | Stock Option (Right to Buy) | 9,206 | 30.46 | 280.4K | 9,206 | D | ↗ |
| 2025-05-22 | Brudnick Richard | Director | A-Award | A | Common Stock | 7,632 | 0.00 | — | 21,132 | D | ↗ |
| 2025-05-22 | AKKARAJU SRINIVAS | Director | A-Award | A | Stock Option (Right to Buy) | 9,206 | 30.46 | 280.4K | 9,206 | D | ↗ |
| 2025-05-02 | Woods Keith | Officer | A-Award | A | Stock Option (Right to Buy) | 110,067 | 32.91 | 3.62M | 110,067 | D | ↗ |
| 2025-05-02 | Vaishnaw Akshay | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 110,067 | 32.91 | 3.62M | 110,067 | D | ↗ |
| 2025-05-02 | Sinha Vikas | Officer | A-Award | A | Stock Option (Right to Buy) | 110,067 | 32.91 | 3.62M | 110,067 | D | ↗ |
| 2025-05-02 | Hallal David | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 275,167 | 32.91 | 9.06M | 275,167 | D | ↗ |
| 2025-04-27 | Woods Keith | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-27 | Vaishnaw Akshay | Director / Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 122,955 | D | ↗ |
| 2025-04-27 | Sinha Vikas | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-27 | Hallal David | Director / Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 554,095 | D | ↗ |
| 2025-04-25 | Sacco Tracey | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 10.00 | 50.0K | 185,000 | D | ↗ |
| 2025-03-24 | Sacco Tracey | Officer | S-Sale | D | Common Stock | 1,500 | 33.70 | 50.6K | 76,750 | D | ↗ |
| 2025-03-24 | Moore Erin | Officer | M-Exempt | A | Common Stock | 8,564 | 13.52 | 115.8K | 96,173 | D | ↗ |
| 2025-03-21 | Moore Erin | Officer | — | — | Stock Option (Right to Buy) | 16,764 | 23.86 | 400.0K | 0 | D | ↗ |
| 2025-03-17 | Peng Katie | Director | S-Sale | D | Common Stock | 1,006 | 34.42 | 34.6K | 30,319 | D | ↗ |
| 2025-03-10 | Sacco Tracey | Officer | A-Award | A | Common Stock | 27,855 | 0.00 | — | 73,250 | D | ↗ |
| 2025-03-10 | Qatanani Mo | Officer | A-Award | A | Stock Option (Right to Buy) | 42,855 | 35.15 | 1.51M | 42,855 | D | ↗ |
| 2025-03-10 | Parlavecchio Caryn | Officer | A-Award | A | Stock Option (Right to Buy) | 31,430 | 35.15 | 1.10M | 31,430 | D | ↗ |
| 2025-03-10 | Myles Edward H | Officer | M-Exempt | D | Stock Option (Right to Buy) | 21,690 | 13.83 | 300.0K | 0 | D | ↗ |
| 2025-03-10 | Marantz Jing L. | Officer | A-Award | A | Common Stock | 34,285 | 0.00 | — | 101,485 | D | ↗ |
| 2025-03-10 | Ho Junlin | Officer | A-Award | A | Stock Option (Right to Buy) | 42,855 | 35.15 | 1.51M | 42,855 | D | ↗ |
| 2025-03-10 | Backstrom Jay T. | Director / Officer | A-Award | A | Common Stock | 113,570 | 0.00 | — | 425,561 | D | ↗ |
| 2025-02-19 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 8,341 | 37.56 | 313.3K | 131,286 | D | ↗ |
| 2025-02-18 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 4,135 | 36.83 | 152.3K | 131,286 | D | ↗ |
| 2025-02-18 | Parlavecchio Caryn | Officer | S-Sale | D | Common Stock | 5,296 | 36.83 | 195.0K | 140,258 | D | ↗ |
| 2025-02-18 | Myles Edward H | Officer | S-Sale | D | Common Stock | 7,809 | 36.83 | 287.6K | 140,740 | D | ↗ |
| 2025-02-18 | Ho Junlin | Officer | S-Sale | D | Common Stock | 5,742 | 36.83 | 211.5K | 189,295 | D | ↗ |
| 2025-02-18 | Backstrom Jay T. | Director / Officer | S-Sale | D | Common Stock | 18,372 | 36.83 | 676.6K | 311,991 | D | ↗ |
| 2025-01-16 | Sacco Tracey | Officer | S-Sale | D | Common Stock | 3,890 | 44.20 | 171.9K | 45,395 | D | ↗ |
| 2025-01-16 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 7,347 | 44.20 | 324.7K | 135,421 | D | ↗ |
| 2025-01-16 | Parlavecchio Caryn | Officer | S-Sale | D | Common Stock | 6,434 | 44.20 | 284.4K | 145,554 | D | ↗ |
| 2025-01-16 | Myles Edward H | Officer | S-Sale | D | Common Stock | 12,539 | 44.20 | 554.2K | 148,549 | D | ↗ |
| 2025-01-16 | Marantz Jing L. | Officer | S-Sale | D | Common Stock | 5,655 | 44.20 | 249.9K | 67,200 | D | ↗ |
| 2025-01-16 | Ho Junlin | Officer | S-Sale | D | Common Stock | 9,039 | 44.20 | 399.5K | 195,037 | D | ↗ |
| 2025-01-16 | Backstrom Jay T. | Director / Officer | S-Sale | D | Common Stock | 22,308 | 44.20 | 986.0K | 330,363 | D | ↗ |
| 2024-12-10 | Invus Public Equities, L.P. | 10% Owner | S-Sale | D | Common Stock | 1,600,000 | 41.65 | 66.64M | 9,250,005 | D | ↗ |
| 2024-11-25 | Marantz Jing L. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,375 | 8.59 | 54.8K | 130,000 | D | ↗ |
| 2024-11-25 | Invus Public Equities, L.P. | 10% Owner | S-Sale | D | Common Stock | 149 | 40.98 | 6.1K | 10,850,005 | D | ↗ |
| 2024-11-22 | Marantz Jing L. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,145 | 8.59 | 18.4K | 136,375 | D | ↗ |
| 2024-11-12 | Gilman Michael | Director | G-Gift | A | Common Stock | 37,459 | 0.00 | — | 50,959 | D | ↗ |
| 2024-11-11 | Marantz Jing L. | Officer | S-Sale | D | Common Stock | 2,105 | 30.00 | 63.2K | 72,855 | D | ↗ |
| 2024-10-08 | Myles Edward H | Officer | M-Exempt | A | Common Stock | 37,187 | 10.00 | 371.9K | 198,275 | D | ↗ |
| 2024-10-07 | Sacco Tracey | Officer | S-Sale | D | Common Stock | 1,964 | 26.23 | 51.5K | 49,285 | D | ↗ |
| 2024-10-07 | Myles Edward H | Officer | M-Exempt | D | Stock Option (Right to Buy) | 165,810 | 13.83 | 2.29M | 0 | D | ↗ |
| 2024-10-07 | Marantz Jing L. | Officer | S-Sale | D | Common Stock | 2,552 | 26.22 | 66.9K | 112,230 | D | ↗ |
| 2024-10-07 | AKKARAJU SRINIVAS | Director | S-Sale | D | Common Stock | 155,713 | 32.50 | 5.06M | 5,612,896 | I | ↗ |
| 2024-09-16 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 1,936 | 8.58 | 16.6K | 142,768 | — | ↗ |
| 2024-08-16 | Parlavecchio Caryn | Officer | S-Sale | D | Common Stock | 1,451 | 9.33 | 13.5K | 151,988 | — | ↗ |
| 2024-07-25 | Siren, L.L.C. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 11,259,438 | — | ↗ |
| 2024-06-27 | Vaishnaw Akshay | Director | A-Award | A | Common Stock | 13,500 | 0.00 | — | 22,955 | — | ↗ |
| 2024-06-27 | Reed Joshua | Director | A-Award | A | Common Stock | 13,500 | 0.00 | — | 13,500 | — | ↗ |
| 2024-06-27 | Peng Katie | Director | A-Award | A | Stock Option (Right to Buy) | 6,000 | 8.36 | 50.2K | 6,000 | — | ↗ |
| 2024-06-27 | Hallal David | Director | A-Award | A | Common Stock | 13,500 | 0.00 | — | 304,095 | — | ↗ |
| 2024-06-27 | Gilman Michael | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 8.36 | 150.5K | 18,000 | — | ↗ |
| 2024-06-27 | FLIER JEFFREY S. | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 8.36 | 150.5K | 18,000 | — | ↗ |
| 2024-06-27 | Burow Kristina | Director | A-Award | A | Common Stock | 13,500 | 0.00 | — | 18,839 | — | ↗ |
| 2024-06-27 | Brudnick Richard | Director | A-Award | A | Common Stock | 13,500 | 0.00 | — | 13,500 | — | ↗ |
| 2024-06-27 | AKKARAJU SRINIVAS | Director | A-Award | A | Common Stock | 13,500 | 0.00 | — | 13,500 | — | ↗ |
| 2024-06-17 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 2,315 | 8.99 | 20.8K | 144,704 | — | ↗ |
| 2024-06-17 | Parlavecchio Caryn | Officer | S-Sale | D | Common Stock | 4,305 | 8.98 | 38.7K | 153,439 | — | ↗ |
| 2024-06-17 | Myles Edward H | Officer | S-Sale | D | Common Stock | 9,458 | 8.98 | 85.0K | 201,518 | — | ↗ |
| 2024-06-17 | Ho Junlin | Officer | S-Sale | D | Common Stock | 4,695 | 8.98 | 42.2K | 204,076 | — | ↗ |
| 2024-05-09 | Nashat Amir | Director | J-Other | D | Common Stock | 472,394 | 0.00 | — | 1,650,953 | — | ↗ |
| 2024-04-09 | Peng Katie | Director | A-Award | A | Stock Option (Right to Buy) | 35,767 | 14.82 | 530.1K | 35,767 | — | ↗ |
| 2024-02-16 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 2,512 | 15.74 | 39.5K | 147,019 | — | ↗ |
| 2024-02-16 | Parlavecchio Caryn | Officer | S-Sale | D | Common Stock | 3,751 | 15.74 | 59.1K | 157,744 | — | ↗ |
| 2024-02-16 | Myles Edward H | Officer | S-Sale | D | Common Stock | 4,744 | 15.74 | 74.7K | 210,976 | — | ↗ |
| 2024-02-16 | Ho Junlin | Officer | S-Sale | D | Common Stock | 3,489 | 15.74 | 54.9K | 208,771 | — | ↗ |
| 2024-02-16 | Backstrom Jay T. | Director / Officer | S-Sale | D | Common Stock | 11,614 | 15.74 | 182.8K | 352,671 | — | ↗ |
| 2024-02-15 | Peng Katie | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-12 | Sacco Tracey | Officer | A-Award | A | Stock Option (Right to Buy) | 65,715 | 15.75 | 1.04M | 65,715 | — | ↗ |
| 2024-02-12 | Qatanani Mo | Officer | A-Award | A | Stock Option (Right to Buy) | 94,285 | 15.75 | 1.48M | 94,285 | — | ↗ |
| 2024-02-12 | Parlavecchio Caryn | Officer | A-Award | A | Stock Option (Right to Buy) | 62,855 | 15.75 | 990.0K | 62,855 | — | ↗ |
| 2024-02-12 | Myles Edward H | Officer | A-Award | A | Stock Option (Right to Buy) | 71,430 | 15.75 | 1.13M | 71,430 | — | ↗ |
| 2024-02-12 | Marantz Jing L. | Officer | A-Award | A | Common Stock | 72,855 | 0.00 | — | 72,855 | — | ↗ |
| 2024-02-12 | Ho Junlin | Officer | A-Award | A | Stock Option (Right to Buy) | 77,145 | 15.75 | 1.22M | 77,145 | — | ↗ |
| 2024-02-12 | Backstrom Jay T. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 285,715 | 15.75 | 4.50M | 285,715 | — | ↗ |
| 2024-01-16 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 2,002 | 15.93 | 31.9K | 78,816 | — | ↗ |
| 2024-01-16 | Parlavecchio Caryn | Officer | S-Sale | D | Common Stock | 2,849 | 15.93 | 45.4K | 114,350 | — | ↗ |
| 2024-01-16 | Myles Edward H | Officer | S-Sale | D | Common Stock | 6,634 | 15.93 | 105.7K | 162,150 | — | ↗ |
| 2024-01-16 | Ho Junlin | Officer | S-Sale | D | Common Stock | 4,186 | 15.93 | 66.7K | 154,405 | — | ↗ |
| 2023-12-29 | Myles Edward H | Officer | M-Exempt | A | Common Stock | 12,459 | 4.86 | 60.6K | 181,243 | — | ↗ |
| 2023-12-27 | Nashat Amir | Director | G-Gift | D | Common Stock | 21,333 | 0.00 | — | 25,506 | — | ↗ |
| 2023-12-21 | Burow Kristina | Director | J-Other | D | Common Stock | 291,906 | 0.00 | — | 2,345,711 | — | ↗ |
| 2023-12-14 | Qatanani Mo | Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,437 | 10.00 | 84.4K | 36,563 | — | ↗ |
| 2023-12-13 | Nashat Amir | Director | J-Other | A | Common Stock | 643 | 0.00 | — | 1,147 | — | ↗ |
| 2023-12-07 | Myles Edward H | Officer | M-Exempt | A | Common Stock | 24,914 | 4.86 | 121.1K | 193,698 | — | ↗ |
| 2023-11-20 | Nashat Amir | Director | J-Other | A | Common Stock | 13,096 | 0.00 | — | 20,537 | — | ↗ |
| 2023-11-02 | Myles Edward H | Officer | S-Sale | D | Common Stock | 35,007 | 12.51 | 438.0K | 168,784 | — | ↗ |
| 2023-10-16 | Samsara BioCapital GP, LLC | 10% Owner | P-Purchase | A | Common Stock | 2,189,781 | 6.85 | 15.00M | 6,788,609 | — | ↗ |
| 2023-10-16 | AKKARAJU SRINIVAS | Director / 10% Owner | P-Purchase | A | Common Stock | 2,189,781 | 6.85 | 15.00M | 6,788,609 | — | ↗ |
| 2023-10-12 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 2,189,781 | 6.85 | 15.00M | 11,249,288 | — | ↗ |
| 2023-09-18 | Qatanani Mo | Officer | S-Sale | D | Common Stock | 1,945 | 6.34 | 12.3K | 97,043 | — | ↗ |
| 2023-08-16 | Parlavecchio Caryn | Officer | S-Sale | D | Common Stock | 1,353 | 6.83 | 9.2K | 117,199 | — | ↗ |
| 2023-06-21 | Vaishnaw Akshay | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 9.11 | 328.0K | 36,000 | — | ↗ |
| 2023-06-21 | Sacco Tracey | Officer | — | D | Stock Option (Right to Buy) | 225,000 | 10.00 | 2.25M | 0 | — | ↗ |
| 2023-06-21 | Reed Joshua | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 9.11 | 328.0K | 36,000 | — | ↗ |
| 2023-06-21 | Qatanani Mo | Officer | — | D | Common Stock | 0 | 0.00 | — | 33,750 | — | ↗ |
| 2023-06-21 | Parlavecchio Caryn | Officer | F-InKind | D | Common Stock | 4,038 | 8.75 | 35.3K | 118,552 | — | ↗ |
| 2023-06-21 | Nashat Amir | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 9.11 | 328.0K | 36,000 | — | ↗ |
| 2023-06-21 | Myles Edward H | Officer | F-InKind | D | Common Stock | 7,138 | 8.75 | 62.5K | 203,791 | — | ↗ |
| 2023-06-21 | Ho Junlin | Officer | F-InKind | D | Common Stock | 4,346 | 8.75 | 38.0K | 158,591 | — | ↗ |
| 2023-06-21 | Hallal David | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 9.11 | 328.0K | 36,000 | — | ↗ |
| 2023-06-21 | Gilman Michael | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 9.11 | 328.0K | 36,000 | — | ↗ |
| 2023-06-21 | FLIER JEFFREY S. | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 9.11 | 328.0K | 36,000 | — | ↗ |
| 2023-06-21 | Burow Kristina | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 9.11 | 328.0K | 36,000 | — | ↗ |
| 2023-06-21 | AKKARAJU SRINIVAS | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 9.11 | 328.0K | 36,000 | — | ↗ |
| 2023-04-28 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 31,557 | 6.43 | 202.8K | 9,059,507 | — | ↗ |
| 2023-04-06 | Brudnick Richard | Director | A-Award | A | Stock Option (Right to Buy) | 56,000 | 7.85 | 439.6K | 56,000 | — | ↗ |
| 2023-02-13 | Parlavecchio Caryn | Officer | A-Award | A | Common Stock | 46,875 | 0.00 | — | 122,590 | — | ↗ |
| 2023-02-13 | Myles Edward H | Officer | A-Award | A | Common Stock | 63,750 | 0.00 | — | 210,929 | — | ↗ |
| 2023-02-13 | Ho Junlin | Officer | A-Award | A | Common Stock | 46,875 | 0.00 | — | 162,937 | — | ↗ |
| 2023-02-13 | Backstrom Jay T. | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 10.00 | 2.00M | 200,000 | — | ↗ |
| 2023-01-17 | Parlavecchio Caryn | Director | F-InKind | D | Common Stock | 2,934 | 11.28 | 33.1K | 75,715 | — | ↗ |
| 2023-01-17 | Myles Edward H | Director | F-InKind | D | Common Stock | 7,043 | 11.29 | 79.5K | 147,179 | — | ↗ |
| 2023-01-17 | Ho Junlin | Director | F-InKind | D | Common Stock | 4,529 | 11.29 | 51.1K | 116,062 | — | ↗ |
| 2023-01-09 | Invus Public Equities, L.P. | Director | S-Sale | D | Common Stock | 1,094 | 9.48 | 10.4K | 9,027,950 | — | ↗ |
| 2023-01-05 | Invus Public Equities, L.P. | Director | P-Purchase | A | Common Stock | 48,774 | 9.33 | 455.1K | 9,029,044 | — | ↗ |
| 2022-11-14 | Marantz Jing L. | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2022-11-09 | Marantz Jing L. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-10-25 | Invus Public Equities, L.P. | Director | P-Purchase | A | Common Stock | 130,265 | 8.04 | 1.05M | 8,980,270 | — | ↗ |
| 2022-10-04 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 66,000 | 7.89 | 520.8K | 8,850,005 | — | ↗ |
| 2022-10-04 | Invus Public Equities Advisors, LLC | Director | P-Purchase | A | Common Stock | 66,000 | 7.89 | 520.8K | 8,850,005 | — | ↗ |
| 2022-10-03 | Invus Public Equities, L.P. | 10% Owner | P-Purchase | A | Common Stock | 33,971 | 7.03 | 238.8K | 8,784,005 | — | ↗ |
| 2022-10-03 | Invus Public Equities Advisors, LLC | Director | P-Purchase | A | Common Stock | 33,971 | 7.03 | 238.8K | 8,784,005 | — | ↗ |
| 2022-09-20 | Backstrom Jay T. | Officer | A-Award | A | Stock Option (right to buy) | 1,000,000 | 8.85 | 8.85M | 1,000,000 | — | ↗ |
| 2022-08-16 | Parlavecchio Caryn | Officer | F-InKind | D | Common Stock | 1,401 | 11.34 | 15.9K | 78,649 | — | ↗ |
| 2022-07-26 | AKKARAJU SRINIVAS | Director | — | I | Common Stock | 0 | 0.00 | — | 4,598,828 | — | ↗ |
| 2022-07-08 | Gilman Michael | Director | G-Gift | A | Common Stock | 37,459 | 0.00 | — | 37,459 | — | ↗ |
| 2022-06-22 | Siren, L.L.C. | 10% Owner | — | D | Warrant (right to buy) | 1,575,008 | 7.35 | 11.58M | 0 | — | ↗ |
| 2022-06-22 | Samsara BioCapital GP, LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 4,598,828 | — | ↗ |
| 2022-06-22 | Nashat Amir | Director | P-Purchase | A | Common Warrant (right to buy) | 16,536 | 7.35 | 121.5K | 16,536 | — | ↗ |
| 2022-06-22 | Invus Public Equities, L.P. | 10% Owner | — | D | Warrant (right to buy) | 1,575,008 | 7.35 | 11.58M | 0 | — | ↗ |
| 2022-06-21 | Samsara BioCapital GP, LLC | 10% Owner | — | I | Warrants to purchase Common Stock | 1,064,804 | 7.35 | 7.83M | 0 | — | ↗ |
| 2022-06-21 | AKKARAJU SRINIVAS | Director | — | I | Warrants to purchase Common Stock | 1,064,804 | 7.35 | 7.83M | 0 | — | ↗ |
| 2022-06-16 | Vaishnaw Akshay | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 4.86 | 68.0K | 14,000 | — | ↗ |
| 2022-06-16 | Parlavecchio Caryn | Officer | A-Award | A | Stock Option (Right to Buy) | 35,750 | 0.00 | — | 35,750 | — | ↗ |
| 2022-06-16 | Myles Edward H | Officer | A-Award | A | Stock Option (Right to Buy) | 74,750 | 0.00 | — | 74,750 | — | ↗ |
| 2022-06-16 | Mahanthappa Nagesh K. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-06-16 | Ho Junlin | Officer | A-Award | A | Stock Option (Right to Buy) | 45,500 | 0.00 | — | 45,500 | — | ↗ |
| 2022-06-16 | Hallal David | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 0.00 | — | 14,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
114.88M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | David Hallal Chief Executive Officer and Chairman | 637.5K | 2.00M | 22.52M | 7.62M | 452.3K | 67.6K | 33.30M | 90.52% | ↗ |
| 2 | 2025 | Jay Backstrom, M.D., M.P.H. Former President and Chief Executive Officer | 600.2K | — | 5.90M | 9.85M | — | 1.15M | 17.49M | 90.02% | ↗ |
| 3 | 2025 | Akshay Vaishnaw, M.D., Ph.D. President of R&D | 523.1K | 2.00M | 9.01M | 3.05M | 278.3K | 32.6K | 14.89M | 80.97% | ↗ |
| 4 | 2025 | R. Keith Woods Chief Operating Officer | 523.1K | — | 9.01M | 3.05M | 278.3K | 57.2K | 12.92M | 93.35% | ↗ |
| 5 | 2025 | Vikas Sinha Chief Financial Officer | 523.1K | — | 9.01M | 3.05M | 278.3K | 14.0K | 12.87M | 93.67% | ↗ |
| 6 | 2024 | Jay Backstrom, M.D., M.P.H. President, and Chief Executive Officer | 649.5K | — | 3.37M | 3.46M | 487.5K | 22.2K | 7.99M | 85.50% | ↗ |
| 7 | 2024 | Jay Backstrom, M.D., M.P.H. Former President and Chief Executive Officer | 649.5K | — | 3.37M | 3.46M | 487.5K | 22.2K | 7.99M | 85.50% | ↗ |
| 8 | 2024 | Jing Marantz, Chief Medical Officer | 492.5K | — | 1.15M | 1.18M | 246.5K | 16.2K | 3.08M | 75.47% | ↗ |
| 9 | 2024 | Mo Qatanani, Chief Scientific Officer | 458.8K | — | 1.11M | 1.14M | 230.0K | 15.9K | 2.96M | 76.19% | ↗ |
| 10 | 2023 | Jay Backstrom, M.D., M.P.H. President, and Chief Executive Officer | 623.5K | — | 1.50M | 1.54M | 430.6K | 17.6K | 4.11M | 73.94% | ↗ |
| 11 | 2023 | Tracey Sacco, Chief Commercial Officer | 367.1K | 25.0K | — | 1.73M | 143.2K | 13.5K | 2.31M | 75.12% | ↗ |
| 12 | 2023 | Edward H. Myles, Chief Operating Officer and Chief Financial Officer | 486.6K | — | 637.5K | 654.6K | 219.6K | 14.5K | 2.01M | 64.19% | ↗ |
| 13 | 2022 | Jay Backstrom, M.D., M.P.H. President and Chief Executive Officer | 159.2K | — | — | 6.81M | 100.6K | 6.9K | 7.08M | 96.23% | ↗ |
| 14 | 2022 | Jay Backstrom, M.D., M.P.H. President, and Chief Executive Officer | 159.2K | — | — | 6.81M | 100.6K | 6.9K | 7.08M | 96.23% | ↗ |
| 15 | 2022 | Edward H. Myles, Chief Operating Officer and Chief Financial Officer | 466.6K | — | 1.40M | 1.04M | 188.2K | 13.7K | 3.11M | 78.50% | ↗ |
| 16 | 2022 | Edward H. Myles, M.B.A. Chief Operating Officer & Chief Financial Officer | 466.6K | — | 1.40M | 1.04M | 188.2K | 13.7K | 3.11M | 78.50% | ↗ |
| 17 | 2022 | Greg Carven, Ph.D. Former Chief Scientific Officer | 333.9K | — | 1.33M | 1.38M | — | 40.6K | 3.09M | 87.87% | ↗ |
| 18 | 2022 | Nagesh K. Mahanthappa, Ph.D. Former Interim Chief Executive Officer and President | 480.6K | — | 1.43M | 862.4K | — | 71.6K | 2.84M | 80.58% | ↗ |
| 19 | 2022 | Junlin Ho, J.D. General Counsel and Secretary | 394.0K | — | 899.1K | 665.5K | 159.2K | 10.5K | 2.13M | 73.51% | ↗ |
| 20 | 2021 | Stuart A. Kingsley Former President and Chief Executive Officer | 318.5K | — | 2.48M | 6.05M | — | 775.4K | 9.62M | 88.62% | ↗ |
| 21 | 2021 | Edward H. Myles, M.B.A. Chief Operating Officer & Chief Financial Officer | 444.8K | — | 1.42M | 3.48M | 158.3K | 12.8K | 5.52M | 88.84% | ↗ |
| 22 | 2021 | Edward H. Myles Chief Operating Officer & Chief Financial Officer | 444.8K | — | 1.42M | 3.48M | 158.3K | 12.8K | 5.52M | 88.84% | ↗ |
| 23 | 2021 | Nagesh K. Mahanthappa, Ph.D. Interim Chief Executive Officer and President | 219.4K | — | — | 4.74M | 128.8K | 8.0K | 5.10M | 93.01% | ↗ |
| 24 | 2021 | Nagesh K. Mahanthappa, Ph.D. Former Interim Chief Executive Officer and President | 219.4K | — | — | 4.74M | 128.8K | 8.0K | 5.10M | 93.01% | ↗ |
| 25 | 2021 | Yung H. Chyung M.D., Chief Medical Officer | 444.8K | — | 928.1K | 2.27M | 158.3K | 10.5K | 3.81M | 83.89% | ↗ |
| 26 | 2020 | Stuart A. Kingsley President and Chief Executive Officer | 238.0K | — | — | 4.40M | 312.0K | 6.7K | 4.95M | 88.76% | ↗ |
| 27 | 2020 | Stuart A. Kingsley Former President and Chief Executive Officer | 238.0K | — | — | 4.40M | 312.0K | 6.7K | 4.95M | 88.76% | ↗ |
| 28 | 2020 | Nagesh K. Mahanthappa, Ph.D. Interim Chief Executive Officer and President | 306.9K | — | 40.7K | 2.94M | — | 846.6K | 4.13M | 72.08% | ↗ |
| 29 | 2020 | Nagesh K. Mahanthappa, Ph.D. Former President and Chief Executive Officer | 306.9K | — | 40.7K | 2.94M | — | 846.6K | 4.06M | 73.36% | ↗ |
| 30 | 2020 | Edward H. Myles Chief Financial Officer & Head of Business Operations | 193.5K | — | — | 2.68M | 209.0K | 30.7K | 3.12M | 86.10% | ↗ |
| 31 | 2020 | Edward H. Myles Chief Operating Officer & Chief Financial Officer | 193.5K | — | — | 2.68M | 209.0K | 30.7K | 3.12M | 86.10% | ↗ |
| 32 | 2020 | Gregory J. Carven Ph.D. Chief Scientific Officer and former Head of Research | 380.8K | — | — | 1.02M | 168.0K | 2.5K | 1.57M | 64.90% | ↗ |
| 33 | 2019 | Nagesh K. Mahanthappa, Ph.D. Former President and Chief Executive Officer | 500.0K | — | — | 1.41M | 250.0K | 3.2K | 2.16M | 65.11% | ↗ |
| 34 | 2019 | Nagesh K. Mahanthappa Ph.D., President and Chief Executive Officer | 500.0K | — | — | 1.41M | 250.0K | 3.2K | 2.16M | 65.11% | ↗ |
| 35 | 2019 | Rhonda M. Chicko, C.P.A, Former Chief Financial Officer | 280.8K | — | — | 746.0K | — | 446.5K | 1.47M | 50.63% | ↗ |
| 36 | 2019 | Yung H. Chyung, M.D., Chief Medical Officer | 416.8K | — | — | 605.4K | 145.9K | 1.4K | 1.17M | 51.77% | ↗ |
| 37 | 2019 | Alan J. Buckler, Chief Scientific Officer | 400.1K | — | — | 551.4K | 140.0K | 2.4K | 1.09M | 50.40% | ↗ |
| 38 | 2018 | Nagesh K. Mahanthappa Ph.D., President and Chief Executive Officer | 456.8K | — | — | 2.31M | 273.1K | 2.3K | 3.04M | 75.93% | ↗ |
| 39 | 2018 | Elan Z. Ezickson, Chief Operating Officer & Head of Corporate Development | 373.9K | — | 1.24M | 42.5K | 133.0K | 24.3K | 1.81M | 70.72% | ↗ |
| 40 | 2018 | Rhonda M. Chicko, C.P.A, Chief Financial Officer | 267.8K | 50.0K | — | 1.18M | 146.1K | 1.4K | 1.64M | 71.66% | ↗ |
| 41 | 2018 | Rhonda M. Chicko, C.P.A, Former Chief Financial Officer | 267.8K | 50.0K | — | 1.18M | 146.1K | 1.4K | 1.64M | 71.66% | ↗ |
| 42 | 2017 | Nagesh K. Mahanthappa Ph.D., President and Chief Executive Officer | 382.5K | — | 590.8K | — | 147.2K | — | 1.12M | 52.73% | ↗ |
| 43 | 2017 | Elan Z. Ezickson, Chief Operating Officer & Head of Corporate Development | 354.4K | — | 108.6K | — | 117.0K | — | 580.1K | 18.73% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David L. Hallal | Chief Executive Officer & Chairman of the Board | 3M | male |
| Robert Keith Woods | Chief Operating Officer | 1M | male |
| Vikas Sinha | CFO & Treasurer | 1M | male |
| Jing L. Marantz | Chief Medical Officer | 755.2K | — |
| Mo Qatanani | Chief Scientific Officer | 704.7K | male |
| Junlin | General Counsel & Corporate Secretary | 563.7K | female |
| Akshay K. Vaishnaw | President of R&D, Member of Scientific Advisory Board and Director | 56.1K | — |
| Lisa Wyman | Chief Technical & Quality Officer | — | female |
| Lisa Amaya Price | Senior Vice President of Human Resources | — | female |
| Rebecca McLeod | Chief Brand Officer & GM of U.S. | — | female |
| Erin Moore | Interim Principal Financial & Accounting Officer | — | female |
| Rushmie Nofsinger | Vice President of Corporate Affairs & Investor Relations | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SRRK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
